TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company dedicated to improving outcomes for patients with solid tumors, particularly those affecting the liver and pancreas. The company's mission is to transform treatment paradigms by integrating innovative drug delivery technology with standard-of-care therapies and investigational immunotherapeutics. Headquartered in Westminster, Colorado, TriSalus Life Sciences aims to address critical barriers that limit the effectiveness of cancer treatments.

The company's core offerings include its proprietary Pressure-Enabled Drug Delivery (PEDD) approach, utilized in FDA-cleared devices such as the TriNav Infusion System, TriNav FLX Infusion System, TriNav XP Infusion System, and the Pancreatic Retrograde Venous Infusion System. These systems are designed to overcome high intratumoral pressure and enhance the targeted delivery of therapeutics to solid tumors. Additionally, TriSalus is developing nelitolimod (formerly SD-101), an investigational class C Toll-like receptor 9 (TLR9) agonist, which aims to reverse immunosuppression within the tumor microenvironment and improve responses to checkpoint inhibitors.

TriSalus Life Sciences became a publicly traded company on August 11, 2023, following a merger with MedTech Acquisition Corporation, with its common stock listed on NASDAQ under the ticker symbol TLSI. Mary Szela serves as the President and CEO. Recent developments include the launch of the TriNav FLX Infusion System in June 2025 and the TriNav XP Infusion System in November 2025, expanding its portfolio of drug delivery technologies. The company also announced preliminary financial results for Q4 and full-year 2025 in January 2026 and completed a public offering in February 2026.